Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

Source: ClinicalTrials.gov results for NCT04269200 (opens in a new tab)· Licence: public-domain

First posted 23 Dec 2025 · Last update posted 7 Aug 2026 · Imported 26 Oct 2026 from ClinicalTrials.gov download 2026-10-25

Primary outcomes with a statistical analysis

1. Progression-free Survival (PFS) According to RECIST 1.1, Based on Investigator Assessments

   Time frame

   At baseline, every 9 weeks (wks) up to 18 wks, then every 12 wks until objective radiological disease progression. Assessed until 12 Apr 2023 DCO (08 Jul 2024 DCO for China cohort), up to 50 months

   Measure

   Median

   Unit

   Months

   • Global Cohort - SoC vs Global Cohort - SoC + DurvalumabSuperiority

     Estimate

     0.71Hazard Ratio (HR)

     95% CI, two-sided

     0.57 to 0.89

     p-value

     0.003

     Method

     Regression, Cox

   • Global Cohort - SoC vs Global Cohort - SoC + Durvalumab + OlaparibSuperiority

     Estimate

     0.55Hazard Ratio (HR)

     95% CI, two-sided

     0.43 to 0.69

     p-value

     <0.0001

     Method

     Regression, Cox

   • China Cohort - SoC vs China Cohort - SoC + DurvalumabSuperiority

     Estimate

     0.73Hazard Ratio (HR)

     95% CI, two-sided

     0.42 to 1.25

     p-value

     Not given

     Method

     Regression, Cox

   • China Cohort - SoC vs China Cohort - SoC + Durvalumab + OlaparibSuperiority

     Estimate

     0.96Hazard Ratio (HR)

     95% CI, two-sided

     0.57 to 1.61

     p-value

     Not given

     Method

     Regression, Cox

Serious adverse events

Time frame: Adverse events (AEs) with onset date or that worsen on or after first dose of study treatment) up until the initiation of the first subsequent anticancer therapy following discontinuation of study treatment or until the end of safety follow-up period (latest of 30 days following discontinuation of olaparib/placebo or 90 days following discontinuation of durvalumab/placebo), whichever occurs first. DCO: 12 Apr 2023 (08 Jul 2024 for China cohort), up to 50 months

Posted results as ClinicalTrials.gov prints them: primary outcome analyses and serious adverse event totals only. Registry facts, not reviewed by HealthTrade and not investment advice; filing-derived results are listed separately.

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.